Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024.

Despite positive trial data, Sarepta Therapeutics has decided to stop the clinical development of SRP-5051 (vesleteplirsen), ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Uy Ear’s rating is based on several positive developments for Sarepta Therapeutics. The company demonstrated strong financial performance in its third quarter of 2024, with revenues surpassing ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...